Bicara Therapeutics logo

Bicara Therapeutics Funding & Investors

Bicara Therapeutics, a wholly-owned subsidiary of Biocon based in Boston, U.S., is developing a pipeline of bifunctional antibodies that exploit the recent advances in immuno-oncology. Bicara enables access to the thriving innovation ecosystem in the U.S. which accelerates the development of cutting-edge therapies for cancer. Synergies between the scientific teams in Boston and Bengaluru will pioneer rapid and cost-effective breakthrough innovation.

bicara.com

Total Amount Raised: $313,000,000

Bicara Therapeutics Funding Rounds

  • Series C

    $165,000,000

    Series C Investors

    Braidwell
    The Rise Fund
    TPG
    Deerfield Management
    Aisling Capital
    Fairmont Capital
    Red Tree Venture Capital.
    Acorn Bioventures
    Invus
    Catalytic Impact Foundation
    Eight Roads Ventures
    Ra Capital Management
    Omega Funds
    Bioqube Ventures
    Piper Heartland Healthcare Capital
    PremjiInvest
    Henderson Global Investors
    F-Prime Capital
  • Series B

    $108,000,000

    Series B Investors

    Ra Capital Management
    Red Tree Venture Capital.
    F-Prime Capital
    Acorn Bioventures
    PremjiInvest
    Piper Heartland Healthcare Capital
    Henderson Global Investors
    Eight Roads Ventures
    Bioqube Ventures
    Omega Funds
    Invus
    Catalytic Impact Foundation
  • Seed

    $40,000,000

    Seed Investors

    Biocon
Funding info provided by Diffbot.